Alemtuzumab

CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

Side effects, and when to stop

The following clinically significant adverse reactions are discussed in greater detail in other sections of the label:

Cytopenias
Infusion-Related Reactions
Immunosuppression/Infections

Who should not take it

None.

Other medicines and interactions

No formal drug interaction studies have been performed with CAMPATH.

Storing it

Store CAMPATH at 2°C to 8°C (36°F to 46°F). Do not freeze. If accidentally frozen, thaw at 2°C to 8°C before administration. Protect from direct sunlight.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Alemtuzumab; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/alemtuzumab
APA 7th: sofidex. (2026, August 2). Alemtuzumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/alemtuzumab
AMA 11th: Alemtuzumab. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/alemtuzumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.